Early Fasting Serum Glucose or Weight Reduction With Tirzepatide and Metabolic Outcomes in People With Type 2 Diabetes: A Post Hoc Analysis of the SURPASS Trials
Both early glucose and weight responses with tirzepatide were associated with better longer-term metabolic outcomes. Early response may be a good clinical indicator that could help inform treatment individualization to achieve therapeutic goals.
Authors
- Ildiko Lingvay (ORCID: https://orcid.org/0000-0001-7006-7401)
- Jacek Kiljański (ORCID: https://orcid.org/0000-0003-0354-0558)
- Amelia Torcello‐Gómez (ORCID: https://orcid.org/0000-0003-3276-1296)
- Francesco Giorgino (ORCID: https://orcid.org/0000-0001-7372-2678)
- Palash Sharma (ORCID: https://orcid.org/0000-0003-3016-7541)
- Ángel Rodríguez (ORCID: https://orcid.org/0000-0001-8721-9539)
- Joshua A. Levine (ORCID: https://orcid.org/0000-0003-1112-2700)
- Luc F. Van Gaal
Institutions
- University of Antwerp (BE)
- Eli Lilly (United States) (US)
- Eli Lilly (Ireland) (IE)
- Antwerp University Hospital (BE)
- University of Bari Aldo Moro (IT)
- The University of Texas Southwestern Medical Center (US)
Publication Details
- Journal
- Diabetes Care
- Published
- 2025-03-18
- DOI
- https://doi.org/10.2337/dc24-2790
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Eli Lilly and Company